ISRCTN02288276
已完成
4 期
A double-blind, randomised, single centre study to evaluate the efficacy of polyhexanide (Prontoderm®) versus placebo for topical decolonisation of methicillin-resistant Staphylococcus aureus (MRSA) carriers
Geneva University Hospitals (Hôpitaux Universitaires de Genève) (Switzerland)0 个研究点目标入组 160 人2011年3月4日
概览
- 阶段
- 4 期
- 干预措施
- 未指定
- 疾病 / 适应症
- 未指定
- 发起方
- Geneva University Hospitals (Hôpitaux Universitaires de Genève) (Switzerland)
- 入组人数
- 160
- 状态
- 已完成
- 最后更新
- 9年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •1\. Aged greater than or equal to 18 years, either sex
- •2\. Microbiologically documented MRSA carriage at any site, without any signs and symptoms of active MRSA infection
- •3\. Written informed consent
排除标准
- •1\. Active MRSA infection
- •2\. Chronic ulcers and deep\-seated wounds colonized by MRSA
- •3\. Presence of tracheostomy
- •4\. Presence of external fixator colonised with MRSA
- •5\. Unavailability of adequate help if subject is unable to self\-administer the investigational product
- •6\. Concurrent treatment with antimicrobial agents with anti\-MRSA activity at the time of enrollment
- •7\. Participation in another prospective clinical trial
- •8\. Previous enrollment in the proposed study
- •9\. Inability to understand or to follow the study protocol
- •10\. Planned cardiac or orthopaedic implant surgery
结局指标
主要结局
未指定
相似试验
Unknown
4 期
A clinical trial to study the effect of 1.5 % Aminexil and 5 % Minoxidil topical solution vs 5 % Minoxidil topical solution in male pattern hair lossHealth Condition 1: null- Male pattern of hair lossCTRI/2011/07/001856Glenmark Pharmaceuticals Ltd40
进行中（未招募）
不适用
A Single Centre, Double-blind, Randomised Study To Investigate a Single Oral Dose of IMD-1041 in A Nasal Allergen Challenge (NAC) ModelIt is intended to investigate the potential therapeutic benefit of IKKß inhibition in man by oral dosing of IMD-1041 in a Nasal Alllergen Challenge.MedDRA version: 14.1Level: PTClassification code 10053467Term: Antiinflammatory therapySystem Organ Class: 10042613 - Surgical and medical proceduresTherapeutic area: Diseases [C] - Ear, nose and throat diseases [C09]EUCTR2007-000190-28-GBInstitute of Medicinal Molecular Design Inc12
进行中（未招募）
不适用
A double-blind, randomized, multi-center study to investigate the endometrial safety of a continuous, combined, oral estrogen/progestin preparation (0.5 mg 17b-estradiol [E2] / 0.25 mg drospirenone [DRSP]) and to compare the bleeding pattern of subjects treated with 0.5 mg E2 / 0.25 mg DRSP with the bleeding pattern of subjects treated with 1.0 mg E2 / 0.5 mg norethisterone acetate (NETA) when used for hormone therapy (HT) for 1 year in post-menopausal women - Angeliq low/low endometrial safety studyEUCTR2006-006199-39-ATBayer Schering Pharma AG600
进行中（未招募）
不适用
A double-blind, randomized, multi-center study to investigate the endometrial safety of a continuous, combined, oral estrogen/progestin preparation (0.5 mg 17b-estradiol [E2] / 0.25 mg drospirenone [DRSP]) and to compare the bleeding pattern of subjects treated with 0.5 mg E2 / 0.25 mg DRSP with the bleeding pattern of subjects treated with 1.0 mg E2 / 0.5 mg norethisterone acetate (NETA) when used for hormone therapy (HT) for 1 year in post-menopausal women - Angeliq low/low endometrial safety studyWomen suffering from postmenopausal symptomsMedDRA version: 9.1Level: LLTClassification code 10050903Term: Postmenopausal symptomsEUCTR2006-006199-39-DKBayer AB, Bayer Schering Pharma600
进行中（未招募）
不适用
A double-blind, randomized, multi-center study to investigate the endometrial safety of a continuous, combined, oral estrogen/progestin preparation (0.5 mg 17β-estradiol [E2] / 0.25 mg drospirenone [DRSP]) and to compare the bleeding pattern of subjects treated with 0.5 mg E2 / 0.25 mg DRSP with the bleeding pattern of subjects treated with 1.0 mg E2 / 0.5 mg norethisterone acetate (NETA) when used for hormone therapy (HT) for 1 year in post-menopausal women - Angeliq low/low endometrial safety studyWomen suffering from postmenopausal symptomsMedDRA version: 9.1Level: SOCClassification code 10014698Term: Endocrine disordersEUCTR2006-006199-39-ITSCHERING600